Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MG-7 antigen-pulsed autologous dendritic cell vaccine
- Development stage
- Phase 2
- Lead developer
- Shanghai Sunstem Biotechnology
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous, Intravenous
01
Overview
MG-7 antigen-pulsed autologous dendritic cell vaccine is an experimental personalized immunotherapy designed to treat gastric cancer. The vaccine is produced by isolating dendritic cells (DCs) from a patient's own peripheral blood, maturing them in vitro, and pulsing them with the MG-7 antigen, a specific gastric cancer-associated antigen. Once re-infused into the patient, these primed dendritic cells act as professional antigen-presenting cells that display MG-7 epitopes to the host's immune system. This process triggers the activation and proliferation of MG-7-specific cytotoxic T lymphocytes (CTLs) and helper T cells, which then selectively target and eliminate MG-7-expressing gastric carcinoma cells. This therapeutic approach is primarily developed by research institutions in China to provide a targeted immune response against tumor recurrence and metastasis in gastric cancer patients.
- Other names
- MG7-Ag-pulsed DC vaccineMG-7-Ag-pulsed DC vaccineMG 7-Ag-pulsed DC vaccineMG7-pulsed autologous dendritic cell vaccineMG-7-pulsed autologous dendritic cell vaccineMG 7-pulsed autologous dendritic cell vaccineMG-7 antigen-loaded dendritic cell vaccineMG7 antigen-loaded dendritic cell vaccineMG 7 antigen-loaded dendritic cell vaccine
02
Targets
CD8A (CD8 alpha/beta Coreceptor)MG7-Ag (Gastric cancer-associated antigen MG7)
Beyond the preview
Go deeper on MG-7 antigen-pulsed autologous dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MG-7 antigen-pulsed autologous dendritic cell vaccine.